Is it possible to prevent ARDS?

JAMA - Journal of the American Medical Association

Volumn 315, Issue 22, 2016, Pages 2403-2405

  Reilly, John P ^a   Christie, Jason D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; CLINICAL TRIAL (TOPIC); CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; EDITORIAL; FLUID RESUSCITATION; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; THROMBOCYTE FUNCTION; TIDAL VOLUME; TIME TO TREATMENT; FEMALE; MALE; RESPIRATORY DISTRESS SYNDROME, ADULT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; HUMANS; MALE; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84974806587     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.5988     Document Type: Editorial

References (15)

1. Duggal A, Ganapathy A, Ratnapalan M, Adhikari NK. Pharmacological treatments for acute respiratory distress syndrome. Minerva Anestesiol. 2015;81(5):567-588.
2. Jacobson JR, Barnard JW, Grigoryev DN, et al. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288(6): L1026-L1032.
3. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006; 116(12):3211-3219.
4. Li G, Malinchoc M, Cartin-Ceba R, et al. Eight-year trend of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183(1): 59-66.
5. Serpa Neto A, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome. JAMA. 2012;308 (16):1651-1659.
6. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled trial of transfusion requirments in critical care. N Engl J Med. 1999;340(6):409-417.
7. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med. 2007;35(7):1645-1648.
8. Kor DJ, Carter RE, Park PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA. doi:10.1001/jama.2016.6330.
9. Shi G, Morrell CN. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res. 2011;127(5):387-390.
10. Tsai MJ, Ou SM, Shih CJ, et al. Association of prior antiplatelet agents with mortality in sepsis patients. Intensive Care Med. 2015;41(5):806-813.
11. Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury. Am J Respir Crit Care Med. 2011;183(4):462-470.
12. Litell JM, Gajic O, Sevransky J, et al. Multicenter consensus development of a checklist for lung injury prevention. Crit Care. 2012;16(suppl 1):504.
13. Agrawal A, Matthay MA, Kangelaris KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med. 2013;187(7):736-742.
14. Herridge MS, Tansey CM, Matté A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14): 1293-1304.
15. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685-1693.